Merck and Moderna vaccine cuts melanoma recurrence by 42% in trial

Merck and Moderna vaccine cuts melanoma recurrence by 42% in trial

Business Health
Sign in to pin this event

Merck and Moderna said their personalized mRNA vaccine intismeran reduced melanoma recurrence by 42% two years after surgery when combined with Keytruda, according to trial data presented in New York. Earlier reports from the same phase-III study also showed a 38% drop in distant metastasis and a comparable reduction in death risk, meeting the companies' expectations. The news caused the firms' shares to fall, and analysts noted the findings could broaden the use of cancer vaccines.

Actors

Moderna Merck TD Cowen RBC Capital Markets

Locations

Wall Street, New York, United States

Fact Check

How these metrics work
Verdict: Partially confirmed Confidence: 60% Claims: 3
At a glance

Three claims were partially confirmed: Merck and Moderna reported on October 22, 2026, that their personalized mRNA vaccine combined with Keytruda reduced the risk of death or recurrence by 42% in patients with resected melanoma; on October 25, 2026, a Merck-Moderna mRNA vaccine with Keytruda lowered melanoma recurrence or death by 42% in a pivotal study; and on October 22, 2026, Merck and Moderna reported their vaccine and Keytruda lowered distant metastasis risk by 38%. One claim stating that on October 23, 2026, in a phase III study, the Moderna-Merck personalized mRNA vaccine intismeran reduced melanoma recurrence and death by 42% compared with Keytruda alone was found to have not enough evidence.

Sign in or subscribe to unlock the full breakdown: claims, sources, and validations.

Sign up Sign in

This section contains an automated verification of claims against external sources and may contain inaccuracies.

Articles

October 25, 2026
2 total
Personalized mRNA vaccine cuts melanoma recurrence risk by 42% in trial
Personalized mRNA vaccine cuts melanoma recurrence risk by 42% in trial

The Globe and Mail • 25 Oct 18:12

A trial of the mRNA-based vaccine intismeran showed a 42% reduction in melanoma recurrence two years after surgery when added to standard therapy.

Credibility 78% Manip. 12% Center
Custom mRNA Vaccine Cuts Melanoma Recurrence Risk in Trial
Custom mRNA Vaccine Cuts Melanoma Recurrence Risk in Trial

STAT • 25 Oct 08:34

A Merck-Moderna mRNA vaccine combined with Keytruda lowered melanoma recurrence or death by 42% in a pivotal study, prompting discussion of broader cancer-vaccine applications.

Credibility 73% Manip. 32% Center
October 23, 2026
1 total
Personalized mRNA vaccine cuts melanoma recurrence risk by 42% in late-stage trial
Personalized mRNA vaccine cuts melanoma recurrence risk by 42% in late-stage trial

NBC News • 23 Oct 18:42

In a phase III study, the Moderna-Merck personalized mRNA vaccine intismeran reduced melanoma recurrence and death by 42% when added to Keytruda, compared with Keytruda alone.

Credibility 71% Manip. 32% Center
October 22, 2026
2 total
Moderna-Merck melanoma vaccine cuts relapse risk by 42% but shares dip
Moderna-Merck melanoma vaccine cuts relapse risk by 42% but shares dip

BioPharma Dive • 22 Oct 22:24

A combined vaccine and Keytruda regimen reduced the relative risk of disease recurrence or death by 42% in advanced melanoma, meeting expectations, while the companies' stocks fell after the announcement.

Credibility 71% Manip. 8% Center
Personalized mRNA vaccine cuts melanoma recurrence and death risk by 42% in Phase 3 trial
Personalized mRNA vaccine cuts melanoma recurrence and death risk by 42% in Phase 3 trial

Ars Technica • 22 Oct 22:12

Merck and Moderna reported that their personalized mRNA vaccine combined with Keytruda reduced the risk of death or recurrence by 42% in patients with resected melanoma, and lowered distant metastasis risk by 38%.

Credibility 78% Manip. 7% Center

Related events